These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16487997)

  • 1. Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.
    Estes JM; Leath CA; Williams S; Modiano MR; Sawyer M; Cohn D; Straughn JM; Barnes MN; Alvarez RD
    Gynecol Oncol; 2006 Aug; 102(2):338-42. PubMed ID: 16487997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Bookman MA; Creasman WT
    Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
    Zhang MM; Chan JK; Husain A; Guo HY; Teng NN
    Gynecol Oncol; 2007 Apr; 105(1):194-8. PubMed ID: 17257661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
    Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ
    Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
    Hensley ML; Hoppe B; Leon L; Sabbatini P; Aghajanian C; Chi D; Spriggs DR
    Gynecol Oncol; 2001 Sep; 82(3):464-9. PubMed ID: 11520141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum.
    Brown JV; Rettenmaier MA; Lopez KL; Graham C; Micha JP; Goldstein B
    Int J Gynecol Cancer; 2008; 18(2):249-54. PubMed ID: 18334007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer.
    Vandenput I; Amant F; Neven P; Berteloot P; Leunen K; Vergote I
    Int J Gynecol Cancer; 2007; 17(1):83-7. PubMed ID: 17291236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
    Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
    J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
    Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.
    Albain KS; Liu PY; Hantel A; Poplin EA; O'Toole RV; Wade JL; Maddox AM; Alberts DS
    Gynecol Oncol; 1995 Jun; 57(3):407-11. PubMed ID: 7774846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Sabbatini P; Aghajanian C; Dizon D; Anderson S; Dupont J; Brown JV; Peters WA; Jacobs A; Mehdi A; Rivkin S; Eisenfeld AJ; Spriggs D
    J Clin Oncol; 2004 Nov; 22(22):4523-31. PubMed ID: 15542803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
    Coleman RL; Broaddus RR; Bodurka DC; Wolf JK; Burke TW; Kavanagh JJ; Levenback CF; Gershenson DM
    Gynecol Oncol; 2006 Apr; 101(1):126-31. PubMed ID: 16271384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.
    Dittrich C; Dieras V; Kerbrat P; Punt C; Sorio R; Caponigro F; Paoletti X; de Balincourt C; Lacombe D; Fumoleau P
    Invest New Drugs; 2003 Aug; 21(3):347-52. PubMed ID: 14578683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
    Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
    Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.